论文部分内容阅读
作者用双盲法研究异搏定预防偏头痛的效果。评价的12例偏头痛病人(无充血性心衰、房室结功能障碍、窦结综合征、肾或肝功能损害以及使用β-阻滞剂或强心甙药物的治疗史),分别在2个试验期接受盐酸异搏定80mg(每天4次)或安慰剂,每个试验期3个月,中间间隔5天,在这期间不服任何预防药。记录每天偏头痛的发作次数、严重性和持续时间,计算头痛单位指数(每天的严重症状发作次数除以发作总数)。研究结果表明,12例中10例在接受异搏定期间的偏头痛发作次数少于接受安慰剂期,平均每例病人每月偏头痛发作次数由安慰剂期的6.7减少到异搏定期的3.8(P<0.05),平均下降49%。平均头痛单位指数
The authors use double-blind study of verapamil to prevent migraine effect. Evaluations of 12 migraineurs (no history of congestive heart failure, atrioventricular node dysfunction, sinus syndrome, renal or hepatic impairment, and treatment with beta-blockers or cardiac glycosides) were performed at 2 A trial of verapamil hydrochloride 80mg (4 times a day) or placebo, each of the three-month trial interval of 5 days, during this period refused to accept any preventive medicine. Record the number, severity, and duration of migraine attacks daily, and calculate the headache unit index (the number of severe symptoms episodes per day divided by the total number of episodes). The study showed that in 10 of 12 patients, the number of migraine attacks was less than placebo during the period of treatment with isosorbide, and the average number of migraine attacks per month per patient decreased from 6.7 for placebo to 3.8 (P <0.05), an average decrease of 49%. Average headache unit index